Galyan Bio plans to initiate a clinical trial of a small molecules candidate that aims to slow the progression of Huntington’s disease next year, working in with Bicoll GmbH. Galyan Bio is developing and optimizing small molecules as oral treatments of Huntington’s and other neurodegenerative disorders, which work by targeting disease-causing mutant…
A teenage boy with a history of parkinsonism was diagnosed with juvenile-onset Huntington’s disease (HD) using high-sensitivity positron emission tomography imaging, known as a PET scan, as described in a recent case study. The study highlights the importance of using appropriate…
Patients with early-onset Huntington’s disease (HD) experience more muscle and eye movement abnormalities, and more rapid progression of motor symptoms, than those with late-onset disease, according to a recent study. According to researchers, the variation in clinical features and disease progression…
Get regular updates to your inbox.